CART cells

 
Shameel Shafqat, Eleze Tariq, Shahrukh K. Hashmi
 
The authors of the abstract conclude: 
Further extensive research needs to be conducted for a better insight into the beneficial long-term effects of gene therapy in FA patients and its potential to become a standard form of treatment.————————————————————————————————————————————————————————
 
 
Chiara F Magnani, Giuseppe Gaipa, Federico Lussana, et al.
 
The authors of the abstract conclude: 
Our data demonstrate that SB-engineered CARCIK-CD19 cells are able to expand and persist in pediatric and adult B-ALL patients relapsed after HSCT, with important implications for allogeneic manufacturing and non-viral technology.
————————————————————————————————————————————————————————
 
 
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, et al.
 
The authors of the abstract conclude: 
Axi-cel demonstrated significant and durable clinical benefit, with high rates of ORR and CR, and a manageable safety profile in patients with R/R iNHL.
 
Visit vjhemonc.com:
————————————————————————————————————————————————————————
 
 
Valentín Ortiz-Maldonado, Susana Rives, Anna Alonso-Saladrigues, et al.
 
The authors of the abstract conclude: 
The administration of ARI-0001 cells, produced in a purely academic setting, provides safety and efficacy results that are comparable with other academic or commercial products. In February 2020 a marketing authorization application under the Hospital Exemption Rule was submitted to the Spanish Medicines Agency. This is a first example showing how academic and Pharma initiatives can be complementary and synergistic in the best interest of patients.
————————————————————————————————————————————————————————
 
 
Mingzhi Zhang, Xiaorui Fu, Lei Zhang, et al.
 
The authors of the abstract conclude: 
CD7-CART cells can be manufactured from patients with CD4/CD8 negative T-ALL/T-LBL without contamination of malignant T cells. CD7-CART therapy is well-tolerated and has great therapeutic potential for patients with relapsed/refractory CD7 positive T cell malignancies. Clinical trial information: NCT04004637.
 
MORE STATEMENTS ABOUT IMMUNO-ONCOLOGY Visit vjhemonc.com